| | | | | | | | | | | | | | | | |
| | |
 | Issue Date FY: 2020 ( Subtotal = -$158 ) |
| | 2020 | 2018 | SPERO LEGACY STI, INC | 675 MASSACHUSETTS AVE STE 14 | CAMBRIDGE | MA | 02139-3309 | MIDDLESEX | USA | R44AI131749 | A Novel Gyrase Inhibitor for the Treatment of Drug-susceptible and Multidrug-resistant Mycobacterium tuberculosis Infections | 000 | 2 | NIH | 4/22/2020 | -$158 |
|
| Issue Date FY: 2019 ( Subtotal = $0 ) |
| | 2019 | 2018 | SPERO LEGACY STI, INC | 675 MASSACHUSETTS AVE STE 14 | CAMBRIDGE | MA | 02139-3309 | MIDDLESEX | USA | R44AI131749 | A Novel Gyrase Inhibitor for the Treatment of Drug-susceptible and Multidrug-resistant Mycobacterium tuberculosis Infections | 000 | 2 | NIH | 11/1/2018 | $0 |
|
| Issue Date FY: 2018 ( Subtotal = $425,178 ) |
| | 2018 | 2018 | SPERO LEGACY STI, INC | 675 MASSACHUSETTS AVE STE 14 | CAMBRIDGE | MA | 02139-3309 | MIDDLESEX | USA | R44AI131749 | A Novel Gyrase Inhibitor for the Treatment of Drug-susceptible and Multidrug-resistant Mycobacterium tuberculosis Infections | 000 | 2 | NIH | 2/23/2018 | $425,178 |
|
| Issue Date FY: 2017 ( Subtotal = $564,718 ) |
| | 2017 | 2017 | SPERO THERAPEUTICS, INC. | 675 MASSACHUSETTS AVE STE 14 | CAMBRIDGE | MA | 02139-3309 | MIDDLESEX | USA | R44AI131749 | A Novel Gyrase Inhibitor for the Treatment of Drug-susceptible and Multidrug-resistant Mycobacterium tuberculosis Infections | 000 | 1 | NIH | 2/22/2017 | $564,718 |
|
|
